Fonge H - Search Results

1

Multifunctional block copolymer micelles for the delivery of 111In to EGFR-positive breast cancer cells for targeted Auger electron radiotherapy.

Fonge H, Lee H, Reilly RM, Allen C. Fonge H, et al. Mol Pharm. 2010 Feb 1;7(1):177-86. doi: 10.1021/mp900201v. Mol Pharm. 2010. PMID: 19924993

2

In vivo distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels.

Lee H, Hoang B, Fonge H, Reilly RM, Allen C. Lee H, et al. Among authors: fonge h. Pharm Res. 2010 Nov;27(11):2343-55. doi: 10.1007/s11095-010-0068-z. Epub 2010 Mar 2. Pharm Res. 2010. PMID: 20195708

3

The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles.

Lee H, Fonge H, Hoang B, Reilly RM, Allen C. Lee H, et al. Among authors: fonge h. Mol Pharm. 2010 Aug 2;7(4):1195-208. doi: 10.1021/mp100038h. Mol Pharm. 2010. PMID: 20476759

4

Influence of formulation variables on the biodistribution of multifunctional block copolymer micelles.

Fonge H, Huang H, Scollard D, Reilly RM, Allen C. Fonge H, et al. J Control Release. 2012 Feb 10;157(3):366-74. doi: 10.1016/j.jconrel.2011.09.088. Epub 2011 Oct 1. J Control Release. 2012. PMID: 21982897

5

Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo.

Chattopadhyay N, Fonge H, Cai Z, Scollard D, Lechtman E, Done SJ, Pignol JP, Reilly RM. Chattopadhyay N, et al. Among authors: fonge h. Mol Pharm. 2012 Aug 6;9(8):2168-79. doi: 10.1021/mp300016p. Epub 2012 Jul 18. Mol Pharm. 2012. PMID: 22734589

6

¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.

Fasih A, Fonge H, Cai Z, Leyton JV, Tikhomirov I, Done SJ, Reilly RM. Fasih A, et al. Among authors: fonge h. Breast Cancer Res Treat. 2012 Aug;135(1):189-200. doi: 10.1007/s10549-012-2137-y. Epub 2012 Jun 27. Breast Cancer Res Treat. 2012. PMID: 22736376

7

Estrone-3-sulphate, a potential novel ligand for targeting breast cancers.

Banerjee N, Fonge H, Mikhail A, Reilly RM, Bendayan R, Allen C. Banerjee N, et al. Among authors: fonge h. PLoS One. 2013 May 22;8(5):e64069. doi: 10.1371/journal.pone.0064069. Print 2013. PLoS One. 2013. PMID: 23717534 Free PMC article.

8

Development of an epidermal growth factor derivative with EGFR blocking activity.

Panosa C, Tebar F, Ferrer-Batallé M, Fonge H, Seno M, Reilly RM, Massaguer A, De Llorens R. Panosa C, et al. Among authors: fonge h. PLoS One. 2013 Jul 30;8(7):e69325. doi: 10.1371/journal.pone.0069325. Print 2013. PLoS One. 2013. PMID: 23935985 Free PMC article.

9

A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.

Panosa C, Fonge H, Ferrer-Batallé M, Menéndez JA, Massaguer A, De Llorens R, Reilly RM. Panosa C, et al. Among authors: fonge h. Nucl Med Biol. 2015 Dec;42(12):931-8. doi: 10.1016/j.nucmedbio.2015.08.003. Epub 2015 Aug 19. Nucl Med Biol. 2015. PMID: 26385534

10

¹¹¹In-Labeled Glycoprotein Nonmetastatic b (GPNMB) Targeted Gemini Surfactant-Based Nanoparticles against Melanoma: In Vitro Characterization and in Vivo Evaluation in Melanoma Mouse Xenograft Model.

Makhlouf A, Hajdu I, Hartimath SV, Alizadeh E, Wharton K, Wasan KM, Badea I, Fonge H. Makhlouf A, et al. Among authors: fonge h. Mol Pharm. 2019 Feb 4;16(2):542-551. doi: 10.1021/acs.molpharmaceut.8b00831. Epub 2019 Jan 18. Mol Pharm. 2019. PMID: 30605337

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

57 results

Search Page

Filters